Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Pfizer License Agreement	Common Stock	Common Stock Pfizer License Agreement	Additional Paid-in Capital	Additional Paid-in Capital Pfizer License Agreement	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Beginning balance at Dec. 31, 2022	$ 160,824		$ 34		$ 373,225			$ (212,435)
Beginning Balance, Shares at Dec. 31, 2022			34,958,730
Issuance of common stock		$ 5,000		$ 2		$ 4,998
Issuance of common stock (Shares)				1,811,594
Issuance of restricted common stock, net of tax withholdings	2		$ 1		1
Issuance of restricted common stock, net of tax withholdings, (Shares)			148,047
Stock-based compensation	4,884				4,884
Net unrealized (loss) gain on marketable debt securities	696						$ 696
Net loss	(19,243)							(19,243)
Ending balance at Mar. 31, 2023	152,163		$ 37		383,108		696	(231,678)
Ending balance (in shares) at Mar. 31, 2023			36,918,371
Beginning balance at Dec. 31, 2022	160,824		$ 34		373,225			(212,435)
Beginning Balance, Shares at Dec. 31, 2022			34,958,730
Shares issued pursuant to the ATM program, net of commission (shares)			1,001,208
Net unrealized (loss) gain on marketable debt securities	(85)
Net loss	(35,144)
Ending balance at Jun. 30, 2023	145,275		$ 39		392,900		(85)	(247,579)
Ending balance (in shares) at Jun. 30, 2023			39,376,941
Beginning balance at Mar. 31, 2023	152,163		$ 37		383,108		696	(231,678)
Beginning Balance, Shares at Mar. 31, 2023			36,918,371
Vesting of restricted common stock (Shares)			1,436,866
Vesting of restricted common stock	1		$ 1
Shares issued pursuant to the ATM program, net of commission (shares)			1,001,208
Shares issued pursuant to the ATM program, net of commission	6,122		$ 1		6,121
Stock options exercised	3				3
Stock options exercised (Shares)			20,496
Stock-based compensation	3,668				3,668
Net unrealized (loss) gain on marketable debt securities	(781)						(781)
Net loss	(15,901)							(15,901)
Ending balance at Jun. 30, 2023	145,275		$ 39		392,900		(85)	(247,579)
Ending balance (in shares) at Jun. 30, 2023			39,376,941
Beginning balance at Dec. 31, 2023	125,704		$ 45		411,821		63	(286,225)
Beginning Balance, Shares at Dec. 31, 2023			44,754,853
Issuance of common stock in private placement, net of offering costs (See Note 7) (Shares)			8,849,371
Issuance of common stock in private placement, net of offering costs (See Note 7)	39,172		$ 9		39,163
Issuance of common stock pursuant to at-the-market program, net of offering costs (See Note 7) (Shares)			3,600,000
Issuance of common stock pursuant to at-the-market program, net of offering costs (See Note 7)	10,590		$ 4		10,586
Issuance of pre-funded warrants in private placement, net of offering costs (See Note 8)	7,700				7,700
Issuance of restricted common stock, net of tax withholdings	(196)		$ 1		(197)
Issuance of restricted common stock, net of tax withholdings, (Shares)			1,497,921
Stock options exercised	245				245
Stock options exercised (Shares)			100,981
Stock-based compensation	4,320				4,320
Net unrealized (loss) gain on marketable debt securities	(123)						(123)
Net loss	(3,256)							(3,256)
Ending balance at Mar. 31, 2024	184,156		$ 59		473,638		(60)	(289,481)
Ending balance (in shares) at Mar. 31, 2024			58,803,126
Beginning balance at Dec. 31, 2023	$ 125,704		$ 45		411,821		63	(286,225)
Beginning Balance, Shares at Dec. 31, 2023			44,754,853
Shares issued pursuant to the ATM program, net of commission (shares)			3,600,000
Stock options exercised (Shares)	122,551
Net unrealized (loss) gain on marketable debt securities	$ (165)
Net loss	(20,557)
Ending balance at Jun. 30, 2024	169,794		$ 59		476,619		(102)	(306,782)
Ending balance (in shares) at Jun. 30, 2024			58,914,712
Beginning balance at Mar. 31, 2024	184,156		$ 59		473,638		(60)	(289,481)
Beginning Balance, Shares at Mar. 31, 2024			58,803,126
Issuance of common stock under employee stock purchase plan ("ESPP")	105				105
Issuance of common stock under employee stock purchase plan ("ESPP") (Shares)			59,882
Issuance of restricted common stock, net of tax withholdings	(43)				(43)
Issuance of restricted common stock, net of tax withholdings, (Shares)			30,553
Stock options exercised	48				48
Stock options exercised (Shares)			21,151
Stock-based compensation	2,871				2,871
Net unrealized (loss) gain on marketable debt securities	(42)						(42)
Net loss	(17,301)							(17,301)
Ending balance at Jun. 30, 2024	$ 169,794		$ 59		$ 476,619		$ (102)	$ (306,782)
Ending balance (in shares) at Jun. 30, 2024			58,914,712